A Visual Guide To How FDA Can Manage The Pandemic
Executive Summary
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.
You may also be interested in...
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.
Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19
If agency has concerns about facilities it cannot inspect, it will generally issue complete responses, Q&A guidance says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: